46
- Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab
for maintenance of clinical response and remission in patients with Crohn’s disease: the
CHARM trial. Gastroenterology. 2007;132(1):52–65. - Colombel JF, Sandborn WJ, Rutgeerts P, Kamm MA, Yu AP, Wu EQ, et al. Comparison of
two adalimumab treatment schedule strategies for moderate-to-severe Crohn’s disease: results
from the CHARM trial. Am J Gastroenterol. 2009;104(5):1170–9. - Panaccione R, Colombel JF, Sandborn WJ, Rutgeerts P, D’Haens GR, Robinson AM, et al.
Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for
Crohn’s disease. Aliment Pharmacol Ther. 2010;31(12):1296–309. - Kamm MA, Hanauer SB, Panaccione R, Colombel JF, Sandborn WJ, Pollack PF, et al.
Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn’s disease.
Aliment Pharmacol Ther. 2011;34(3):306–17. - Panaccione R, Colombel JF, Sandborn WJ, D’Haens G, Zhou Q, Pollack PF, et al. Adalimumab
maintains remission of Crohn’s disease after up to 4 years of treatment: data from CHARM
and ADHERE. Aliment Pharmacol Ther. 2013;38(10):1236–47. - Louis E, Lofberg R, Reinisch W, Camez A, Yang M, Pollack PF, et al. Adalimumab improves
patient-reported outcomes and reduces indirect costs in patients with moderate to severe
Crohn’s disease: results from the CARE trial. J Crohns Colitis. 2013;7(1):34–43. - Loftus EV, Feagan BG, Colombel JF, Rubin DT, Wu EQ, Yu AP, et al. Effects of adalimumab
maintenance therapy on health-related quality of life of patients with Crohn’s disease: patient-
reported outcomes of the CHARM trial. Am J Gastroenterol. 2008;103(12):3132–41. - Panaccione R, Loftus EV Jr, Binion D, McHugh K, Alam S, Chen N, et al. Efficacy and safety
of adalimumab in Canadian patients with moderate to severe Crohn’s disease: results of the
Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn’s DiseaSe (ACCESS)
trial. Can J Gastroenterol. 2011;25(8):419–25. - Loftus EV Jr, Johnson SJ, Yu AP, Wu EQ, Chao J, Mulani PM. Cost-effectiveness of adalim-
umab for the maintenance of remission in patients with Crohn’s disease. Eur J Gastroenterol
Hepatol. 2009;21(11):1302–9. - Feagan BG, Panaccione R, Sandborn WJ, D’Haens GR, Schreiber S, Rutgeerts PJ, et al.
Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn’s disease:
results from the CHARM study. Gastroenterology. 2008;135(5):1493–9. - Rutgeerts P, Van Assche G, Sandborn WJ, Wolf DC, Geboes K, Colombel JF, et al. Adalimumab
induces and maintains mucosal healing in patients with Crohn’s disease: data from the
EXTEND trial. Gastroenterology. 2012;142(5):1102–11.e2. - Colombel JF, Rutgeerts PJ, Sandborn WJ, Yang M, Camez A, Pollack PF, et al. Adalimumab
induces deep remission in patients with Crohn’s disease. Clin Gastroenterol Hepatol.
2014;12(3):414–22.e5. - Dewint P, Hansen BE, Verhey E, Oldenburg B, Hommes DW, Pierik M, et al. Adalimumab
combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula clo-
sure in Crohn’s disease: a randomised, double-blind, placebo controlled trial (ADAFI). Gut.
2014;63(2):292–9. - Winter TA, Wright J, Ghosh S, Jahnsen J, Innes A, Round P. Intravenous CDP870, a
PEGylated Fab’ fragment of a humanized antitumour necrosis factor antibody, in patients
with moderate-to-severe Crohn’s disease: an exploratory study. Aliment Pharmacol Ther.
2004;20(11-12):1337–46. - Schreiber S, Rutgeerts P, Fedorak RN, Khaliq-Kareemi M, Kamm MA, Boivin M, et al. A
randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn’s
disease. Gastroenterology. 2005;129(3):807–18. - Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, et al. Certolizumab
pegol for the treatment of Crohn’s disease. N Engl J Med. 2007;357(3):228–38. - Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OO, Hanauer SB, McColm J,
et al. Maintenance therapy with certolizumab pegol for Crohn’s disease. N Engl J Med.
2007;357(3):239–50.
B. P. Va u g h n